The Benzene Ring Is Attached To Nitrogen Through An Acyclic Carbon Or Carbon Chain Patents (Class 514/487)
-
Patent number: 11731991Abstract: Augmented or synergized anti-inflammatory constructs are disclosed including anti-inflammatory terpenes and/or vanilloids covalently conjugated to one another so that the activity of the conjugate is greater than the sum of its parts. Also disclosed are methods of improving the potency of an anti-inflammatory terpene or vanilloid by linking it to another anti-inflammatory terpene or vanilloid via a carbamate linkage, where the potency of the conjugate is greater than the sum of its parts.Type: GrantFiled: August 12, 2020Date of Patent: August 22, 2023Assignees: LEHIGH UNIVERSITY, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Jeffrey D. Laskin, Diane E. Heck, Carl J. Lacey, Ned D. Heindel, Sherri C. Young
-
Patent number: 9695071Abstract: A method of treating mineral slurries to inhibit bacterial growth includes adding an effective amount of one or more of sodium N-methyldithiocarbamate or methylammonium monomethyldithiocarbamate to the mineral slurry to inhibit bacterial growth.Type: GrantFiled: July 8, 2016Date of Patent: July 4, 2017Assignee: BULK CHEMICAL SERVICES, LLC.Inventor: Seth Spurlock
-
Patent number: 9265748Abstract: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxyl)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.Type: GrantFiled: July 14, 2015Date of Patent: February 23, 2016Assignee: XenoPort, Inc.Inventors: Stephen P. Raillard, Suresh K. Manthati, Sudhir Joshi
-
Patent number: 9139517Abstract: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.Type: GrantFiled: November 11, 2013Date of Patent: September 22, 2015Assignee: XenoPort, Inc.Inventors: Stephen P. Raillard, Suresh K. Manthati, Sudhir Joshi
-
Patent number: 9034922Abstract: A composition for maintaining a function of platelets, the composition comprising, as an active ingredient, a compound represented by the following general formula (I) or a salt thereof, or a solvate thereof: wherein X represents a phenylene group; Y represents any one of a hydrogen atom and —(CH2)mR1; wherein m represents an integer of any one of 0 to 4; and R1 is any one of —NR5COR2, —NR5SO2R2, and —NR3R4; wherein R2 represents any one of a C1 to C6 alkyl group, an aryl group, a C1 to C6 alkoxy group, and the like; R3 and R4 represent a C1 to C6 alkyl group or the like; and R5 represents any one of a hydrogen atom, a C1 to C6 alkyl group, and the like; and Z represents any one of a hydrogen atom and a C1 to C6 alkyl group.Type: GrantFiled: September 16, 2011Date of Patent: May 19, 2015Assignees: THE UNIVERSITY OF TOKYO, KAKEN PHARMACEUTICAL CO., LTD.Inventors: Koji Eto, Ryoko Ohnishi, Hiromitsu Nakauchi, Takahiko Murata
-
Publication number: 20150133541Abstract: A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided.Type: ApplicationFiled: January 13, 2015Publication date: May 14, 2015Inventor: Yong Moon Choi
-
Patent number: 9029589Abstract: A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a composition for muscle relaxation containing the phenyl alkyl carbamate derivative compounds and/or pharmaceutically acceptable salt thereof as an active ingredient, and a method of muscle relaxation comprising administering a pharmaceutically effective amount of the phenyl alkyl carbamate derivative compound and/or a pharmaceutically acceptable salt thereof to a subject in need of to a subject in need of, are provided.Type: GrantFiled: December 27, 2012Date of Patent: May 12, 2015Assignee: Bio-Pharm Solutions Co., Ltd.Inventor: Yong Moon Choi
-
Patent number: 9018253Abstract: A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided.Type: GrantFiled: July 1, 2011Date of Patent: April 28, 2015Assignee: Bio-Pharm Solutions Co., Ltd.Inventor: Yong Moon Choi
-
Publication number: 20140378460Abstract: This invention relates to the use sigma-2 receptor antagonists, and of pharmaceutical compositions comprising such compounds, in methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology and more broadly treating with such compounds and compositions neurodegenerative diseases and disorders associated with Abeta pathology. This invention also relates to methods for screening compounds for activity in inhibiting cognitive decline on the basis of their ability to bind to a sigma-2 receptor.Type: ApplicationFiled: August 27, 2012Publication date: December 25, 2014Applicant: COGNITION THERAPEUTICS, INC.Inventors: Susan M. Catalano, Gilbert Rishton, Nicholas J. Izzo
-
Publication number: 20140342989Abstract: A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula Ia, or more particularly Formula Ib: or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.Type: ApplicationFiled: July 31, 2014Publication date: November 20, 2014Inventors: Harold L. Kohn, Christophe Salome, Elise Salome-Grosjean
-
Publication number: 20140323436Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein W is O or S; V is a direct bond or NR3; Q is or CR6aR6b, O, NR7, C?N—O—R7 or C(?O); Y is —C(R5)?N—O—(CR8aR8b)p—X—(CR9aR9b)q—SiR10aR10bR10c; or a phenyl ring substituted as defined in the disclosure; or Z; and R1, R2, R3, R4, R5, R6a, R6b, R7, R8a, R8b, R9a, R9b, R10a, R10b, R10c, Z, p and q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.Type: ApplicationFiled: July 8, 2014Publication date: October 30, 2014Inventors: Bruce Lawrence FINKELSTEIN, Andrew Edmund TAGGI, Jeffrey Keith LONG, Paula Louise SHARPE, Chi-Ping TSENG, Stephen Frederick MCCANN, Amy X DING, Steven Lewis SWANN, JR.
-
Publication number: 20140296334Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.Type: ApplicationFiled: October 14, 2011Publication date: October 2, 2014Inventors: Jennifer Riggs-Sauthier, Wen Zhang
-
Publication number: 20140275243Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating a pediatric epilepsy or epilepsy-related syndrome comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating pediatric epilepsy or pediatric epilepsy-related syndromes.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: BIO-PHARM SOLUTIONS CO., LTD.Inventor: YONG MOON CHOI
-
Publication number: 20140163077Abstract: The present disclosure relates to novel compounds, compositions containing same and methods for treating or preventing a condition associated with a deficient insulin secretion such as diabetes and metabolic syndrome in a subject in need thereof.Type: ApplicationFiled: July 31, 2012Publication date: June 12, 2014Applicant: VAL-CHUM, LIMITED PARTNERSHIPInventors: Murthy S.R. Madiraju, Marc Prentki, Erik Joly
-
Patent number: 8686032Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers:Type: GrantFiled: December 1, 2010Date of Patent: April 1, 2014Assignee: Chroma Therapeutics Ltd.Inventors: Alan Hornsby Davidson, Sanjay Ratilal Patel, Francesca Ann Mazzei, Stephen John Davies, Alan Hastings Drummond, David Festus Moffat, Kenneth William John Baker, Alistair David Graham Donald
-
Publication number: 20140066501Abstract: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.Type: ApplicationFiled: November 11, 2013Publication date: March 6, 2014Applicant: XenoPort, Inc.Inventors: Stephen P. Raillard, Suresh K. Manthati, Sudhir Joshi
-
Publication number: 20140051753Abstract: A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided.Type: ApplicationFiled: July 1, 2011Publication date: February 20, 2014Applicant: Bio-Pharm Solutions Co., Ltd.Inventor: Yong Moon Choi
-
Patent number: 8580850Abstract: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.Type: GrantFiled: August 10, 2012Date of Patent: November 12, 2013Assignee: XenoPort, Inc.Inventors: Stephen P. Raillard, Suresh K. Manthati, Sudhir Joshi
-
Publication number: 20130203846Abstract: A composition for treating and/or preventing ALS containing the phenyl carbamate compound or a pharmaceutically acceptable salt thereof as an active ingredient; a method of treating and/or preventing ALS comprising administering the phenyl carbamate compound or a pharmaceutically acceptable salt thereof to a patient in need of ALS treatment; and a use of the phenyl carbamate compound or a pharmaceutically acceptable salt thereof in treating and/or preventing ALS, are provided.Type: ApplicationFiled: December 27, 2012Publication date: August 8, 2013Applicant: Bio-Pharm Solutions Co., Ltd.Inventor: Bio-Pharm Solutions Co., Ltd.
-
Publication number: 20130184222Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.Type: ApplicationFiled: July 15, 2011Publication date: July 18, 2013Applicant: AGIOS PHARMACEUTICALS, INCInventors: Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey Saunders, Jeremy Travins, Shunqi Yan
-
Publication number: 20130184338Abstract: A phenyl carbamate compound, and a method of treating and/or preventing multiple sclerosis comprising administering a pharmaceutically effective amount of the phenyl carbamate compound to a subject in need of treating and/or preventing multiple sclerosis, are provided.Type: ApplicationFiled: December 27, 2012Publication date: July 18, 2013Applicant: Bio-Pharm Solutions Co., Ltd.Inventor: Bio-Pharm Solutions Co., Ltd.
-
Publication number: 20130165509Abstract: A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a composition for muscle relaxation containing the phenyl alkyl carbamate derivative compounds and/or pharmaceutically acceptable salt thereof as an active ingredient, and a method of muscle relaxation comprising administering a pharmaceutically effective amount of the phenyl alkyl carbamate derivative compound and/or a pharmaceutically acceptable salt thereof to a subject in need of to a subject in need of, are provided.Type: ApplicationFiled: December 27, 2012Publication date: June 27, 2013Applicant: Bio-Pharm Solutions Co., Ltd.Inventor: Bio-Pharm Solutions Co., Ltd.
-
Publication number: 20130150410Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with ion channel modulators. In these methods, the ion channel modulator compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the ion channel modulator compositions and formulations onto the auris interna target areas, or via perfusion into the auris interna structures.Type: ApplicationFiled: February 7, 2013Publication date: June 13, 2013Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, OTONOMY, INC.Inventors: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIF
-
Patent number: 8461189Abstract: The present invention relates to a novel class of pyridyl and pyrimidinyl derivatives. The pyridyl and pyrimidinyl compounds can be used to treat cancer. The pyridyl and pyrimidinyl compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: GrantFiled: June 24, 2008Date of Patent: June 11, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Richard W. Heidebrecht, Jr., Thomas A. Miller, Matthew G. Stanton, David J. Witter
-
Publication number: 20130137720Abstract: The present invention provides compounds, or derivatives or prodrugs thereof, that comprise a methyllysine mimic, and an ?-ketoglutarate mimic that are attached through a linker and methods for using and producing the same. In some embodiments, compounds of the invention are of the formula: M-L-K, or a derivative or a prodrug thereof, wherein M is a methyllysine mimic, L is a linker, and K is an ?-ketoglutarate mimic.Type: ApplicationFiled: November 30, 2012Publication date: May 30, 2013Applicant: The Regents of the University of Colorado, a body corporatedInventors: Xiang Wang, Wenqing Xu
-
Publication number: 20130116318Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers:Type: ApplicationFiled: December 1, 2010Publication date: May 9, 2013Applicant: Chroma Therapeutics Ltd.Inventors: Alan Hornsby Davidson, Sanjay Ratilal Patel, Francesca Ann Mazzei, Stephen John Davies, Alan Hastings Drummond, David Festus Moffat, Kenneth William John Baker, Alistair David Graham Donald
-
Publication number: 20130096127Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: November 29, 2012Publication date: April 18, 2013Applicant: NOVARTIS AGInventor: NOVARTIS AG
-
Patent number: 8415501Abstract: The present invention is directed to methods and compositions for making and using a new polymorph of cinacalcet hydrochloride.Type: GrantFiled: March 22, 2007Date of Patent: April 9, 2013Assignee: Amgen, Inc.Inventors: Belle B. Liu, Pengzu Zhou, Nina Cauchon
-
Patent number: 8389553Abstract: The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: GrantFiled: June 24, 2008Date of Patent: March 5, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Paul Harrington, Solomon Kattar, Thomas A. Miller, Matthew G. Stanton, Paul Tempest, David J. Witter
-
Patent number: 8377956Abstract: Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid for treating urinary incontinence is disclosed.Type: GrantFiled: March 1, 2011Date of Patent: February 19, 2013Assignee: XenoPort, Inc.Inventors: Aetna W. Wun, David J. Wustrow
-
Publication number: 20130041026Abstract: Crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid anhydrate and crystalline (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl)butanoic acid hemihydrate, pharmaceutical compositions comprising such compounds, methods of making and methods of using the same are disclosed.Type: ApplicationFiled: August 10, 2012Publication date: February 14, 2013Applicant: XENOPORT, INC.Inventors: Stephen P. Raillard, Suresh K. Manthati, Sudhir Joshi
-
Publication number: 20130005801Abstract: A novel phenylcarbamate compound and a pharmaceutical composition containing the same are provided. More specifically, a novel phenylcarbamate compound, a composition for muscle relaxation containing the phenylcarbamate compound as an active ingredient, and a method of muscle relaxation comprising administering a therapeutically effective amount of the phenylcarbamate compound, are provided.Type: ApplicationFiled: July 1, 2011Publication date: January 3, 2013Applicant: Bio-Pharm Solutions Co., Ltd.Inventor: Yong Moon Choi
-
Patent number: 8309129Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, ethylcellulose, and a bile salt.Type: GrantFiled: April 21, 2008Date of Patent: November 13, 2012Assignee: Bend Research, Inc.Inventors: Warren Kenyon Miller, Michael Mark Morgen, Daniel Tod Smithey
-
Publication number: 20120264784Abstract: Subjects having elevated signaling of a mammalian target of rapamycin (mTOR) are treated with compositions that include at least one compound that activates a Group 1 mGluR. In an embodiment, the subject has tuberous sclerosis complex (TSC). In an embodiment, the compound is a Group 1 mGluR agonist. In another embodiment, the compound is a Group 1 mGluR positive allosteric modulator.Type: ApplicationFiled: April 25, 2012Publication date: October 18, 2012Inventors: Mark F. Bear, Benjamin David Auerbach
-
Publication number: 20120202854Abstract: Compounds of formula (I): in which R1, R2, R7, R8, R9, R10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.Type: ApplicationFiled: April 17, 2012Publication date: August 9, 2012Applicant: ARRAY BIOPHARMA INC.Inventors: George Doherty, Adam Cook
-
Publication number: 20120148560Abstract: A pharmaceutical composition for treating or preventing one or both of neural anoxia and reperfusion injury, which includes a pharmacological activator of the PKG pathway, and methods of treating or preventing medical conditions using a pharmacological activator of the PKG pathway.Type: ApplicationFiled: December 15, 2011Publication date: June 14, 2012Applicant: Florida Atlantic UniversityInventors: Kenneth DAWSON-SCULLY, Sara Louise Milton
-
Patent number: 8163953Abstract: Compounds useful for promoting lysosomal processes and thereby ameliorating the disruption of cellular and functional integrity induced by A? and other protein and glycoconjugate species are provided. Methods for the treatment of neurodegenerative diseases that involve protein accumulation and aggregation in the brain, such as Alzheimer's, Parkinson's and Huntington's Disease, are also provided.Type: GrantFiled: April 20, 2009Date of Patent: April 24, 2012Assignee: University of ConnecticutInventors: Ben A. Bahr, Dennis Wright
-
Publication number: 20120053238Abstract: The invention relates to solid retigabine in non-crystalline form together with a surface stabiliser in the form of a stable intermediate. In the intermediate of the invention, retigabine is preferably present in amorphous form or in the form of a solid solution. The invention further relates to processes for the production of retigabine in a solid, non-crystalline form and to pharmaceutical formulations containing solid, non-crystalline retigabine.Type: ApplicationFiled: March 17, 2010Publication date: March 1, 2012Applicant: ratiopharm GmbHInventors: Jana Paetz, Katrin Rimkus
-
Publication number: 20120046358Abstract: A method for preventing and treating prostatic diseases and skin cancer using naturally or artificially synthesized isothiocyanates compounds or the derivatives or metabolites thereof.Type: ApplicationFiled: September 13, 2011Publication date: February 23, 2012Applicant: WUXI JC PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Jingcai Cheng, Jenwei Chiao, Haiya Jin, Chengjuan Zhong
-
Publication number: 20120016021Abstract: Disclosed herein are methods of treating fragile X syndrome, fragile X-associated tremor/ataxia syndrome, Down's syndrome and other forms of mental retardation, and/or autism comprising administering a GABAB agonist prodrug to a subject suffering therefrom. The GABAB agonist prodrugs can be compounds of Formula (I), (II) or (III) as disclosed herein.Type: ApplicationFiled: July 15, 2011Publication date: January 19, 2012Applicant: XENOPORT, INC.Inventors: David J. Wustrow, Peter A. Virsik, Mark A. Gallop
-
Publication number: 20110312903Abstract: Methods for fluorinating organic compounds are described herein.Type: ApplicationFiled: November 20, 2009Publication date: December 22, 2011Inventors: Tobias Ritter, Takeru Furuya, PingPing Tang
-
Publication number: 20110294876Abstract: The present invention relates to the cosmetic, dermatological or therapeutic use of compounds of formula (I) given below, in particular as anti-ageing actives. wherein A denotes wherein X, Y and Z independently of one another denote hydrogen, C1-C4-alkyl or C2-C4-alkenyl, wherein optionally two of the radicals X, Y and Z are covalently bonded to one another under formation of a bicyclic ring system, in such a bicyclic ring system two of the radicals X, Y and Z together preferably form a radical having 1 to 4 carbon atoms, preferably a hydrocarbon radical having 1 to 3 carbon atoms, B denotes NR1R2, wherein R1 denotes hydrogen or an organic radical having 1 to 14 carbon atoms, R2 denotes an organic radical having 1 to 14 carbon atoms, and wherein optionally R1 and R2 are covalently bonded to one another, preferably so that B is a 3 to 8 membered ring.Type: ApplicationFiled: May 6, 2011Publication date: December 1, 2011Applicant: SYMRISE AGInventors: Thomas Küper, Heiko Oertling, Tilman Grune, Matthias Saathoff, Martina Herrmann, Julia Betke, Claudia Gömann, Rahim Brodhage, Imke Meyer
-
Publication number: 20110269761Abstract: The invention relates to substituted aryl-sulphonylglycine derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as in the specification and claims, which are suitable for preparing a pharmaceutical composition for the treatment of metabolic disorders, particularly type 1 or type 2 diabetes mellitus.Type: ApplicationFiled: April 17, 2009Publication date: November 3, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Elke Langkopf, Frank Himmelsbach, Juergen Mack, Alexander Pautsch, Corinna Schoelch, Annette Schuler-Metz, Ruediger Streicher, Holger Wagner
-
Publication number: 20110251175Abstract: The invention relates to methods for the treatment or prevention of substance use disorders.Type: ApplicationFiled: July 16, 2009Publication date: October 13, 2011Inventors: Nadia Rupniak, James F. White
-
Publication number: 20110212984Abstract: Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence is disclosed.Type: ApplicationFiled: March 1, 2011Publication date: September 1, 2011Applicant: XenoPort, Inc.Inventors: Aetna W. Wun, David J. Wustrow
-
Publication number: 20110144177Abstract: Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.Type: ApplicationFiled: February 22, 2011Publication date: June 16, 2011Inventors: Jeroen C. Verheijen, ShouCheng Du
-
Publication number: 20110098352Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: ApplicationFiled: January 29, 2009Publication date: April 28, 2011Applicant: AMIRA PHARMACEUTICALS, INC.Inventors: John Howard Hutchinson, Brian Andrew Stearns, Jill Melissa Scott, Yen Pham Truong, Jeffrey Roger Roppe, Nicholas Simon Stock, Jeannie M. Arruda, Thomas Jon Seiders, Bowei Wang
-
Publication number: 20110053941Abstract: Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprisType: ApplicationFiled: December 1, 2008Publication date: March 3, 2011Applicant: NEWLINK GENETICSInventors: Mario Mautino, Firoz Jaipuri, Agnieszka Marcinowicz-Flick, Tanay Kesharwani, Jesse Waldo, Steven James Collier
-
Publication number: 20110021571Abstract: The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.Type: ApplicationFiled: September 16, 2010Publication date: January 27, 2011Applicant: XenoPort, Inc.Inventors: Mark A. Gallop, Fenmei Yao, Maria J. Ludwikow, Thu Phan, Ge Peng
-
Publication number: 20100324046Abstract: The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: ApplicationFiled: June 24, 2008Publication date: December 23, 2010Inventors: Paul Harrington, Richard W. Heidebrecht, JR., Solomon Kattar, Thomas A. Miller, Karin M. Otte, Phieng Siliphaivanh, Paul Tempest, Kevin J. Wilson, David J. Witter